ID   RD-ES
AC   CVCL_2169
SY   RDES; RDES-1
DR   BTO; BTO:0004202
DR   CLO; CLO_0008774
DR   EFO; EFO_0002316
DR   CLDB; cl4128
DR   CLDB; cl4129
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; HTB-166
DR   BCRJ; 0267
DR   BioGRID_ORCS_Cell_line; 194
DR   BioSample; SAMN03470929
DR   BioSample; SAMN10987904
DR   cancercelllines; CVCL_2169
DR   Cell_Model_Passport; SIDM01316
DR   CLS; 300410
DR   Cosmic; 759890
DR   Cosmic; 1078386
DR   Cosmic; 1082506
DR   Cosmic; 1085906
DR   Cosmic; 1381107
DR   Cosmic; 1718429
DR   Cosmic; 2228230
DR   Cosmic; 2250477
DR   Cosmic; 2294586
DR   DepMap; ACH-000041
DR   DSMZ; ACC-260
DR   DSMZCellDive; ACC-260
DR   GDSC; 1330996
DR   GEO; GSM393042
DR   GEO; GSM510006
DR   GEO; GSM887527
DR   GEO; GSM888609
DR   GEO; GSM1676310
DR   GEO; GSM1701644
DR   IARC_TP53; 1272
DR   IARC_TP53; 8400
DR   IGRhCellID; RDES
DR   LiGeA; CCLE_906
DR   LINCS_LDP; LCL-1455
DR   PharmacoDB; RDES_1297_2019
DR   Progenetix; CVCL_2169
DR   Wikidata; Q54949536
RX   DOI=10.5282/edoc.27750;
RX   PubMed=8040301;
RX   PubMed=8221663;
RX   PubMed=8378080;
RX   PubMed=9738976;
RX   PubMed=11423975;
RX   PubMed=18082704;
RX   PubMed=18160777;
RX   PubMed=19787792;
RX   PubMed=20215515;
RX   PubMed=21822310;
RX   PubMed=22142829;
RX   PubMed=22460905;
RX   PubMed=25010205;
RX   PubMed=25223734;
RX   PubMed=25877200;
RX   PubMed=26351324;
RX   PubMed=26428435;
RX   PubMed=28196595;
RX   PubMed=29464090;
RX   PubMed=30879952;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: ~60 hours (DSMZ=ACC-260).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=18160777; PubMed=19787792).
CC   Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (PubMed=8040301; PubMed=9738976; PubMed=11423975; PubMed=25010205).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=8221663; PubMed=8378080; PubMed=19787792; PubMed=25010205; PubMed=25223734; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.21%; Native American=0.02%; East Asian, North=3.1%; East Asian, South=0%; South Asian=0%; European, North=61.77%; European, South=33.89% (PubMed=30894373).
CC   Derived from site: In situ; Bone, humerus; UBERON=UBERON_0000976.
ST   Source(s): ATCC; CLS; DSMZ; PubMed=19787792; PubMed=25010205; PubMed=25877200; PubMed=30879952
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 11,12
ST   D16S539: 9,11
ST   D18S51: 14,18
ST   D19S433: 13,14
ST   D21S11: 28
ST   D2S1338: 19,20
ST   D3S1358: 15
ST   D5S818: 11
ST   D7S820: 10
ST   D8S1179: 13
ST   FGA: 21,25
ST   Penta D: 9,12
ST   Penta E: 11,13
ST   SE33: 17,18
ST   TH01: 7
ST   TPOX: 9,11
ST   vWA: 17
DI   NCIt; C4817; Ewing sarcoma
DI   ORDO; Orphanet_319; Ewing sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   19Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 40
//
RX   DOI=10.5282/edoc.27750;
RA   Orth M.F.;
RT   "Systematic multi-omics profiling of Ewing sarcoma cell lines.";
RL   Thesis PhD (2021), Ludwig Maximilians University of Munich, Germany.
//
RX   PubMed=8040301; DOI=10.1172/JCI117360;
RA   Giovannini M., Biegel J.A., Serra M., Wang J.-Y., Wei Y.-L.H., Nycum L.,
RA   Emanuel B.S., Evans G.A.;
RT   "EWS-erg and EWS-Fli1 fusion transcripts in Ewing's sarcoma and
RT   primitive neuroectodermal tumors with variant translocations.";
RL   J. Clin. Invest. 94:489-496(1994).
//
RX   PubMed=8221663;
RA   Komuro H., Hayashi Y., Kawamura M., Hayashi K., Kaneko Y.,
RA   Kamoshita S., Hanada R., Yamamoto K., Hongo T., Yamada M., Tsuchida Y.;
RT   "Mutations of the p53 gene are involved in Ewing's sarcomas but not in
RT   neuroblastomas.";
RL   Cancer Res. 53:5284-5288(1993).
//
RX   PubMed=8378080;
RA   Kovar H., Auinger A., Jug G., Aryee D.N.T., Zoubek A.,
RA   Salzer-Kuntschik M., Gadner H.;
RT   "Narrow spectrum of infrequent p53 mutations and absence of MDM2
RT   amplification in Ewing tumours.";
RL   Oncogene 8:2683-2690(1993).
//
RX   PubMed=9738976; DOI=10.1111/j.1349-7006.1998.tb03274.x;
RA   Urano F., Umezawa A., Yabe H., Hong W., Yoshida K., Fujinaga K.,
RA   Hata J.-i.;
RT   "Molecular analysis of Ewing's sarcoma: another fusion gene, EWS-E1AF,
RT   available for diagnosis.";
RL   Jpn. J. Cancer Res. 89:703-711(1998).
//
RX   PubMed=11423975; DOI=10.1038/sj.onc.1204437;
RA   Dauphinot L., De Oliveira C., Melot T., Sevenet N., Thomas V.,
RA   Weissman B.E., Delattre O.;
RT   "Analysis of the expression of cell cycle regulators in Ewing cell
RT   lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression.";
RL   Oncogene 20:3258-3265(2001).
//
RX   PubMed=18082704; DOI=10.1016/j.jpedsurg.2007.08.026;
RA   Komuro H., Saihara R., Shinya M., Takita J., Kaneko S., Kaneko M.,
RA   Hayashi Y.;
RT   "Identification of side population cells (stem-like cell population)
RT   in pediatric solid tumor cell lines.";
RL   J. Pediatr. Surg. 42:2040-2045(2007).
//
RX   PubMed=18160777; DOI=10.1159/000109614;
RA   Savola S., Nardi F., Scotlandi K., Picci P., Knuutila S.;
RT   "Microdeletions in 9p21.3 induce false negative results in CDKN2A FISH
RT   analysis of Ewing sarcoma.";
RL   Cytogenet. Genome Res. 119:21-26(2007).
//
RX   PubMed=19787792; DOI=10.1002/gcc.20717;
RA   Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E.,
RA   Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H.,
RA   Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W.,
RA   Buerger H., Aigner T., Gabbert H.E., Poremba C.;
RT   "Molecular characterization of commonly used cell lines for bone tumor
RT   research: a trans-European EuroBoNet effort.";
RL   Genes Chromosomes Cancer 49:40-51(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21822310; DOI=10.1038/onc.2011.317;
RA   Mackintosh C., Ordonez J.L., Garcia-Dominguez D.J., Sevillano V.,
RA   Llombart-Bosch A., Szuhai K., Scotlandi K., Alberghini M., Sciot R.,
RA   Sinnaeve F., Hogendoorn P.C.W., Picci P., Knuutila S., Dirksen U.,
RA   Debiec-Rychter M., Schaefer K.-L., de Alava E.;
RT   "1q gain and CDT2 overexpression underlie an aggressive and highly
RT   proliferative form of Ewing sarcoma.";
RL   Oncogene 31:1287-1298(2012).
//
RX   PubMed=22142829; DOI=10.1158/1078-0432.CCR-11-2056;
RA   Shukla N., Ameur N., Yilmaz I., Nafa K., Lau C.-Y., Marchetti A.,
RA   Borsu L., Barr F.G., Ladanyi M.;
RT   "Oncogene mutation profiling of pediatric solid tumors reveals
RT   significant subsets of embryonal rhabdomyosarcoma and neuroblastoma
RT   with mutated genes in growth signaling pathways.";
RL   Clin. Cancer Res. 18:748-757(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25010205; DOI=10.1371/journal.pgen.1004475;
RA   Brohl A.S., Solomon D.A., Chang W., Wang J.-J., Song Y., Sindiri S.,
RA   Patidar R., Hurd L., Chen L., Shern J.F., Liao H.-L., Wen X.-Y.,
RA   Gerard J., Kim J.-S., Lopez Guerrero J.A., Machado I., Wai D.H.,
RA   Picci P., Triche T.J., Horvai A.E., Miettinen M.M., Wei J.S.,
RA   Catchpoole D., Llombart-Bosch A., Waldman T., Khan J.;
RT   "The genomic landscape of the Ewing sarcoma family of tumors reveals
RT   recurrent STAG2 mutation.";
RL   PLoS Genet. 10:E1004475-E1004475(2014).
//
RX   PubMed=25223734; DOI=10.1158/2159-8290.CD-14-0622;
RA   Tirode F., Surdez D., Ma X.-T., Parker M., Le Deley M.-C., Bahrami A.,
RA   Zhang Z.-J., Lapouble E., Grossetete-Lalami S., Rusch M., Reynaud S.,
RA   Rio-Frio T., Hedlund E., Wu G., Chen X., Pierron G., Oberlin O.,
RA   Zaidi S., Lemmon G., Gupta P., Vadodaria B., Easton J., Gut M.,
RA   Ding L., Mardis E.R., Wilson R.K., Shurtleff S., Laurence V.,
RA   Michon J., Marec-Berard P., Gut I.G., Downing J.R., Dyer M.A.,
RA   Zhang J.-H., Delattre O.;
RT   "Genomic landscape of Ewing sarcoma defines an aggressive subtype with
RT   co-association of STAG2 and TP53 mutations.";
RL   Cancer Discov. 4:1342-1353(2014).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=26428435; DOI=10.1016/j.ejca.2015.08.020;
RA   Sand L.G.L., Scotlandi K., Berghuis D., Snaar-Jagalska B.E., Picci P.,
RA   Schmidt T., Szuhai K., Hogendoorn P.C.W.;
RT   "CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate
RT   with survival and metastases in Ewing sarcoma patients.";
RL   Eur. J. Cancer 51:2624-2633(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29464090; DOI=10.18632/oncotarget.23815;
RA   Spurny C., Kailayangiri S., Altvater B., Jamitzky S., Hartmann W.,
RA   Wardelmann E., Ranft A., Dirksen U., Amler S., Hardes J., Fluegge M.,
RA   Meltzer J., Farwick N., Greune L., Rossig C.;
RT   "T cell infiltration into Ewing sarcomas is associated with local
RT   expression of immune-inhibitory HLA-G.";
RL   Oncotarget 9:6536-6549(2018).
//
RX   PubMed=30879952; DOI=10.1016/j.ymthe.2019.02.014;
RA   Kailayangiri S., Altvater B., Lesch S., Balbach S.T., Gottlich C.,
RA   Kuhnemundt J., Mikesch J.-H., Schelhaas S., Jamitzky S., Meltzer J.,
RA   Farwick N., Greune L., Fluegge M., Kerl K., Lode H.N., Siebert N.,
RA   Muller I., Walles H., Hartmann W., Rossig C.;
RT   "EZH2 inhibition in Ewing sarcoma upregulates GD2 expression for
RT   targeting with gene-modified T cells.";
RL   Mol. Ther. 27:933-946(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//